Niquitin Sabor Menta (Nicotine)

Nicotine, the active ingredient in Niquitin Sabor Menta, is a nicotine replacement therapy presented as an oromucosal form for oral use. It is used to aid smoking cessation in adult smokers seeking to reduce nicotine dependence. It delivers nicotine through the mucosal membranes, providing a controlled dose that mitigates withdrawal symptoms and cravings associated with quitting tobacco.

GNH USA supplies Niquitin Sabor Menta as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide, complying with European Union regulations for consistent quality.

Niquitin Sabor Menta is a nicotine replacement therapy used in the management of nicotine dependence and tobacco withdrawal. - Smoking cessation: helps adult smokers reduce cravings and withdrawal symptoms while transitioning away from cigarettes. - Tobacco use disorder: provides a controlled nicotine dose to support gradual reduction of tobacco consumption. - Relapse prevention: assists individuals who have quit smoking to maintain abstinence by alleviating occasional urges.

Common and serious adverse reactions have been reported with oromucosal nicotine products.

Common Side Effects: - Mouth irritation - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, or anaphylaxis) - Cardiovascular events (palpitations, hypertension, or arrhythmia)

Before using Niquitin Sabor Menta, consider the following precautions. - Assess nicotine dependence before initiating therapy: determine baseline use and withdrawal risk. - Do not use if allergic to nicotine or any excipients in the product. - Monitor cardiovascular status in patients with known heart disease or hypertension. - Avoid concurrent use of other nicotine‑containing products to prevent overdose. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Niquitin Sabor Menta may interact with other medicines; review the following.

Major Interactions (Avoid): - Concomitant use with other nicotine‑containing products: risk of nicotine overdose. - Use with monoamine oxidase inhibitors (MAOIs): may increase hypertensive response. - Use with beta‑blockers: nicotine‑induced tachycardia may be masked.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., methoxsalen): may raise nicotine plasma levels. - Alcohol consumption: can enhance nicotine’s cardiovascular effects. - Caffeine intake: may increase incidence of headache and jitteriness.